Symptom-triggered medication for neonatal opioid withdrawal yields shorter hospital stays

BOSTON – A study led by researchers at Boston Medical Center (BMC) found that symptom-triggered medication dosing for neonatal opioid withdrawal syndrome instead of infants receiving a fixed schedule of medication with a long taper reduced the length of their hospital stay. The findings, published in Hospital Pediatrics, indicate that following the novel symptom-triggered approach…

Details

Hinge-like protein may open new doors in cystic fibrosis treatment

IMAGE: A potentiator (orange) binds to a protein ‘hotspot,’ altering the molecule’s conformation. view more  Credit: Laboratory of Membrane Biology and Biophysics at The Rockefeller University In recent decades, treatment options for people with cystic fibrosis have improved dramatically. The newest drugs, known as potentiators, target a protein called cystic fibrosis transmembrane conductance regulator, which is…

Details

UM researchers land NIH contract to develop opioid addiction vaccine

IMAGE: Montana Gov. Steve Bullock (right) meets with Dr. Jay Evans, director of UM’s Center for Translational Medicine. view more  Credit: University of Montana file photo MISSOULA – The University of Montana has received a $3.3 million contract from the National Institutes of Health to develop an innovative vaccine targeting opioid addiction. The principal investigator on…

Details

University of Pittsburgh group brings computation and experimentation closer together

IMAGE: Frames from a 10 hour long time-lapse sequence with model prediction (red line) and explant spreading (dotted line). ‘Good’ models predict not only the extent of the movement but also… view more  Credit: MechMorpho Lab/University of Pittsburgh PITTSBURGH (July 9, 2019) … A bioengineering group from the University of Pittsburgh Swanson School of Engineering is…

Details